Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

454.96
-0.7500-0.16%
Post-market: 454.960.00000.00%19:56 EST
Volume:1.26M
Turnover:573.48M
Market Cap:115.43B
PE:31.99
High:459.05
Open:455.71
Low:452.83
Close:455.71
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.03
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.22
EPS(LYR):-2.0768
ROE:22.31%
ROA:12.04%
PB:6.67
PE(LYR):-219.07

Loading ...

Vertex Pharmaceuticals announces updated data from RUBY-3 study of povetacicept

TIPRANKS
·
Nov 10

A Fresh Look at Vertex (VERX) Valuation After Q3 Earnings, Guidance Cut, and $150M Buyback

Simply Wall St.
·
Nov 09

Assessing Vertex Pharmaceuticals (VRTX) Valuation as Shares Pause After Strong Multi-Year Gains

Simply Wall St.
·
Nov 09

Vertex Presents Updated Phase 1/2 Data From Ruby-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults With Iga Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

THOMSON REUTERS
·
Nov 09

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Reuters
·
Nov 08

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Nov 08

Vertex Pharmaceuticals Is Maintained at Buy by UBS

Dow Jones
·
Nov 08

UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating

MT Newswires Live
·
Nov 07

CORRECTED-UPDATE 1-US FDA awards six more fast-track vouchers to speed drug reviews

Reuters
·
Nov 07

BRIEF-FDA Announces Six Additional Awardees Under The CNPV Pilot Program

Reuters
·
Nov 07

Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies

Reuters
·
Nov 06

Vertex Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Nov 06

Vortex Energy Corp. Advances Hydrogen Storage Research at Canadian Convention

TIPRANKS
·
Nov 06

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Agilon Health (AGL) and REPRO-MED Systems (KRMD)

TIPRANKS
·
Nov 06

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Nov 05

Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights

TIPRANKS
·
Nov 05

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Nov 05

Stock Track | Vertex Pharmaceuticals Plummets 5.27% Following Mixed Q3 Results and Analyst Downgrades

Stock Track
·
Nov 04

Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration

TIPRANKS
·
Nov 04

Morgan Stanley Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Nov 04